Listed

Medicinova Inc

MNOVNasdaqCIK 1226616HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$458.4k, Q2 FY2026
Operating income−$2.5m, Q2 FY2026
Net income−$2.3m, Q2 FY2026
Medicinova Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$k1,000Revenue, Q3 FY2023, three months to 2023-09-30$1.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-19, accession 0000950170-25-023301. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reported135Revenue, Q2 FY2025, three months to 2025-06-30$134.6k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure123Revenue, Q3 FY2025, three months to 2025-09-30$123.3k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure152Revenue, Q4 FY2025, three months to 2025-12-31$151.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure187Revenue, Q1 FY2026, three months to 2026-03-31$187.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure458Revenue, Q2 FY2026, three months to 2026-06-30$458.4k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Cost of revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k700Research and development, Q3 FY2023, three months to 2023-09-30$700.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure1,600Research and development, Q4 FY2023, three months to 2023-12-31$1.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-19, accession 0000950170-25-023301. Derived: 12-month figure less the 9-month figure.Report this figure1,700Research and development, Q1 FY2024, three months to 2024-03-31$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure1,500Research and development, Q2 FY2024, three months to 2024-06-30$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure1,800Research and development, Q3 FY2024, three months to 2024-09-30$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure1,800Research and development, Q4 FY2024, three months to 2024-12-31$1.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure1,700Research and development, Q1 FY2025, three months to 2025-03-31$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure2,000Research and development, Q2 FY2025, three months to 2025-06-30$2.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure1,500Research and development, Q3 FY2025, three months to 2025-09-30$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure1,400Research and development, Q4 FY2025, three months to 2025-12-31$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure1,200Research and development, Q1 FY2026, three months to 2026-03-31$1.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure900Research and development, Q2 FY2026, three months to 2026-06-30$900.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Operating income$k(1,147)Operating income, Q3 FY2023, three months to 2023-09-30−$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure(2,490)Operating income, Q4 FY2023, three months to 2023-12-31−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-19, accession 0000950170-25-023301. Derived: 12-month figure less the 9-month figure.Report this figure(3,136)Operating income, Q1 FY2024, three months to 2024-03-31−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure(3,046)Operating income, Q2 FY2024, three months to 2024-06-30−$3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure(3,309)Operating income, Q3 FY2024, three months to 2024-09-30−$3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure(3,184)Operating income, Q4 FY2024, three months to 2024-12-31−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure(3,203)Operating income, Q1 FY2025, three months to 2025-03-31−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure(3,607)Operating income, Q2 FY2025, three months to 2025-06-30−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure(3,381)Operating income, Q3 FY2025, three months to 2025-09-30−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure(3,092)Operating income, Q4 FY2025, three months to 2025-12-31−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure(2,836)Operating income, Q1 FY2026, three months to 2026-03-31−$2.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure(2,541)Operating income, Q2 FY2026, three months to 2026-06-30−$2.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Interest expense$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(723)Net income, Q3 FY2023, three months to 2023-09-30−$723.1k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure(2,059)Net income, Q4 FY2023, three months to 2023-12-31−$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-19, accession 0000950170-25-023301. Derived: 12-month figure less the 9-month figure.Report this figure(2,755)Net income, Q1 FY2024, three months to 2024-03-31−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure(2,628)Net income, Q2 FY2024, three months to 2024-06-30−$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure(2,852)Net income, Q3 FY2024, three months to 2024-09-30−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure(2,815)Net income, Q4 FY2024, three months to 2024-12-31−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure(2,864)Net income, Q1 FY2025, three months to 2025-03-31−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure(3,281)Net income, Q2 FY2025, three months to 2025-06-30−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure(3,050)Net income, Q3 FY2025, three months to 2025-09-30−$3.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure(2,802)Net income, Q4 FY2025, three months to 2025-12-31−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure(2,586)Net income, Q1 FY2026, three months to 2026-03-31−$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure(2,314)Net income, Q2 FY2026, three months to 2026-06-30−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Diluted EPS$ per share(0.01)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figurenot reported(0.06)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure(0.05)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure(0.06)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figurenot reported(0.06)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure(0.07)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure(0.06)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figurenot reported(0.05)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure(0.05)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Basic EPS$ per share(0.01)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figurenot reported(0.06)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure(0.05)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure(0.06)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figurenot reported(0.06)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure(0.07)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure(0.06)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.06 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figurenot reported(0.05)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure(0.05)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure

Balance sheet

Cash and equivalents$25.4m, Q2 FY2026
Shareholders' equity$37.3m, Q2 FY2026
Medicinova Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m51.5Cash and equivalents, Q3 FY2023, at 2023-09-30$51.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0000950170-23-062079.Report this figure51.0Cash and equivalents, FY2023, at 2023-12-31$51.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-19, accession 0000950170-25-023301.Report this figure47.1Cash and equivalents, Q1 FY2024, at 2024-03-31$47.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0000950170-24-056996.Report this figure44.3Cash and equivalents, Q2 FY2024, at 2024-06-30$44.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0000950170-24-094092.Report this figure42.3Cash and equivalents, Q3 FY2024, at 2024-09-30$42.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure40.4Cash and equivalents, FY2024, at 2024-12-31$40.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-10, accession 0001193125-26-100432.Report this figure36.6Cash and equivalents, Q1 FY2025, at 2025-03-31$36.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure34.3Cash and equivalents, Q2 FY2025, at 2025-06-30$34.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure32.6Cash and equivalents, Q3 FY2025, at 2025-09-30$32.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure30.8Cash and equivalents, FY2025, at 2025-12-31$30.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure27.3Cash and equivalents, Q1 FY2026, at 2026-03-31$27.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure25.4Cash and equivalents, Q2 FY2026, at 2026-06-30$25.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Current assets$m53.0Current assets, Q3 FY2023, at 2023-09-30$53.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062079.Report this figure51.2Current assets, FY2023, at 2023-12-31$51.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-19, accession 0000950170-25-023301.Report this figure47.9Current assets, Q1 FY2024, at 2024-03-31$47.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056996.Report this figure45.5Current assets, Q2 FY2024, at 2024-06-30$45.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094092.Report this figure43.3Current assets, Q3 FY2024, at 2024-09-30$43.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure41.1Current assets, FY2024, at 2024-12-31$41.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-10, accession 0001193125-26-100432.Report this figure37.7Current assets, Q1 FY2025, at 2025-03-31$37.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure35.1Current assets, Q2 FY2025, at 2025-06-30$35.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure32.9Current assets, Q3 FY2025, at 2025-09-30$32.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure31.0Current assets, FY2025, at 2025-12-31$31.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure28.1Current assets, Q1 FY2026, at 2026-03-31$28.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure25.9Current assets, Q2 FY2026, at 2026-06-30$25.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Total assets$m68.1Total assets, Q3 FY2023, at 2023-09-30$68.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0000950170-23-062079.Report this figure66.3Total assets, FY2023, at 2023-12-31$66.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-19, accession 0000950170-25-023301.Report this figure62.9Total assets, Q1 FY2024, at 2024-03-31$62.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-056996.Report this figure60.4Total assets, Q2 FY2024, at 2024-06-30$60.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-094092.Report this figure58.1Total assets, Q3 FY2024, at 2024-09-30$58.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure55.9Total assets, FY2024, at 2024-12-31$55.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-10, accession 0001193125-26-100432.Report this figure52.4Total assets, Q1 FY2025, at 2025-03-31$52.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure49.8Total assets, Q2 FY2025, at 2025-06-30$49.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure47.6Total assets, Q3 FY2025, at 2025-09-30$47.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure45.6Total assets, FY2025, at 2025-12-31$45.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure42.7Total assets, Q1 FY2026, at 2026-03-31$42.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure40.4Total assets, Q2 FY2026, at 2026-06-30$40.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Current liabilities$m2.8Current liabilities, Q3 FY2023, at 2023-09-30$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062079.Report this figure3.3Current liabilities, FY2023, at 2023-12-31$3.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-19, accession 0000950170-25-023301.Report this figure2.5Current liabilities, Q1 FY2024, at 2024-03-31$2.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056996.Report this figure2.5Current liabilities, Q2 FY2024, at 2024-06-30$2.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094092.Report this figure2.6Current liabilities, Q3 FY2024, at 2024-09-30$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure3.0Current liabilities, FY2024, at 2024-12-31$3.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-10, accession 0001193125-26-100432.Report this figure2.1Current liabilities, Q1 FY2025, at 2025-03-31$2.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure2.6Current liabilities, Q2 FY2025, at 2025-06-30$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure3.3Current liabilities, Q3 FY2025, at 2025-09-30$3.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure3.8Current liabilities, FY2025, at 2025-12-31$3.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure3.1Current liabilities, Q1 FY2026, at 2026-03-31$3.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure3.0Current liabilities, Q2 FY2026, at 2026-06-30$3.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Total liabilities$m3.5Total liabilities, Q3 FY2023, at 2023-09-30$3.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0000950170-23-062079.Report this figure3.9Total liabilities, FY2023, at 2023-12-31$3.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-19, accession 0000950170-25-023301.Report this figure3.1Total liabilities, Q1 FY2024, at 2024-03-31$3.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-056996.Report this figure3.0Total liabilities, Q2 FY2024, at 2024-06-30$3.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-094092.Report this figure3.1Total liabilities, Q3 FY2024, at 2024-09-30$3.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure3.4Total liabilities, FY2024, at 2024-12-31$3.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-10, accession 0001193125-26-100432.Report this figure2.5Total liabilities, Q1 FY2025, at 2025-03-31$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure3.0Total liabilities, Q2 FY2025, at 2025-06-30$3.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure3.6Total liabilities, Q3 FY2025, at 2025-09-30$3.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure4.0Total liabilities, FY2025, at 2025-12-31$4.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure3.3Total liabilities, Q1 FY2026, at 2026-03-31$3.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure3.2Total liabilities, Q2 FY2026, at 2026-06-30$3.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m64.7Shareholders' equity, Q3 FY2023, at 2023-09-30$64.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure62.4Shareholders' equity, FY2023, at 2023-12-31$62.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-10, accession 0001193125-26-100432.Report this figure59.8Shareholders' equity, Q1 FY2024, at 2024-03-31$59.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure57.4Shareholders' equity, Q2 FY2024, at 2024-06-30$57.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure55.1Shareholders' equity, Q3 FY2024, at 2024-09-30$55.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure52.5Shareholders' equity, FY2024, at 2024-12-31$52.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure49.9Shareholders' equity, Q1 FY2025, at 2025-03-31$49.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure46.9Shareholders' equity, Q2 FY2025, at 2025-06-30$46.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure44.0Shareholders' equity, Q3 FY2025, at 2025-09-30$44.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure41.6Shareholders' equity, FY2025, at 2025-12-31$41.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure39.4Shareholders' equity, Q1 FY2026, at 2026-03-31$39.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure37.3Shareholders' equity, Q2 FY2026, at 2026-06-30$37.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure

Cash flow

Operating cash flow−$1.9m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Medicinova Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(1,372)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0000950170-24-126343. Derived: 9-month figure less the 6-month figure.Report this figure(499)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$499.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-19, accession 0000950170-25-023301. Derived: 12-month figure less the 9-month figure.Report this figure(3,868)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure(2,811)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0000950170-25-109041. Derived: 6-month figure less the 3-month figure.Report this figure(2,032)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277779. Derived: 9-month figure less the 6-month figure.Report this figure(1,932)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure(3,784)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$3.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure(2,306)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$2.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349323. Derived: 6-month figure less the 3-month figure.Report this figure(1,703)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277779. Derived: 9-month figure less the 6-month figure.Report this figure(2,017)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure(3,470)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure(1,920)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349323. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$k2.7Capital expenditure, Q3 FY2023, three months to 2023-09-30$2.7k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0000950170-24-126343. Derived: 9-month figure less the 6-month figure.Report this figure(0.0)Capital expenditure, Q4 FY2023, three months to 2023-12-31−$22. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-19, accession 0000950170-25-023301. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$6. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277779. Derived: 9-month figure less the 6-month figure.Report this figure(0.0)Capital expenditure, Q4 FY2024, three months to 2024-12-31−$2. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349323. Derived: 6-month figure less the 3-month figure.Report this figure2.9Capital expenditure, Q3 FY2025, three months to 2025-09-30$2.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277779. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-10, accession 0001193125-26-100432. Derived: 12-month figure less the 9-month figure.Report this figure10.8Capital expenditure, Q1 FY2026, three months to 2026-03-31$10.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349323. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)49.22m, Q2 FY2026
Medicinova Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q1 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares49.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3049,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0000950170-23-062079.Report this figure49.0Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3149,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-056996.Report this figure49.0Diluted shares (weighted), Q1 FY2023, three months to 2023-06-3049,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-094092.Report this figure49.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3049,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0000950170-24-126343.Report this figure49.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3149,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0000950170-25-070461.Report this figure49.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3049,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0000950170-25-109041.Report this figure49.0Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3049,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure49.0Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3149,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure49.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3049,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure49.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3049,046,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277779.Report this figure49.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3149,221,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001193125-26-224066.Report this figure49.2Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3049,221,246 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure

Shares outstanding: 49.22mShares outstanding, period not labelled, at 2026-08-1149,221,246 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349323.Report this figure at Aug 11, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.